12.02.13
SpinalCyte LLC, a spinal technology company focused on autologous regrowth of the spinal disc nucleus using human dermal fibroblasts, has been granted a patent in Australia to regrow the spinal disc using human dermal fibroblasts. The allowed claims include the use of human dermal fibroblasts from the patient’s own body, to regrow the nucleus of the spinal disc in vivo.
“This is the sixth international patent in our growing patent portfolio and it distinguishes SpinalCyte as a leader for regeneration of the spinal disc,” CEO Pete O’Heeron said. “This is our second Australian patent and we are excited the Australian Patent Office validated our technology. Regenerative medicine is leading the rapidly growing movement toward biologics, cell therapy and gene therapy and we believe our focus on autologous regrowth of cartilage will provide an eventual cure for all forms of cartilage degradation.”
The nucleus pulposus is a gelatinous material that acts as a cushion or shock absorber to the spinal column. It functions to distribute hydraulic pressure in all directions within each disc under compressive loads. The nucleus pulposus consists of chondrocytes, collagenfibrils, and proteoglycan aggrecans.
Based in Houston, Texas, SpinalCyte LLC is a spinal technology company founded in 2007 to develop an autologous solution for nucleus replacement using human dermal fibroblasts. The company has been funded entirely by angel investors.
“This is the sixth international patent in our growing patent portfolio and it distinguishes SpinalCyte as a leader for regeneration of the spinal disc,” CEO Pete O’Heeron said. “This is our second Australian patent and we are excited the Australian Patent Office validated our technology. Regenerative medicine is leading the rapidly growing movement toward biologics, cell therapy and gene therapy and we believe our focus on autologous regrowth of cartilage will provide an eventual cure for all forms of cartilage degradation.”
The nucleus pulposus is a gelatinous material that acts as a cushion or shock absorber to the spinal column. It functions to distribute hydraulic pressure in all directions within each disc under compressive loads. The nucleus pulposus consists of chondrocytes, collagenfibrils, and proteoglycan aggrecans.
Based in Houston, Texas, SpinalCyte LLC is a spinal technology company founded in 2007 to develop an autologous solution for nucleus replacement using human dermal fibroblasts. The company has been funded entirely by angel investors.